# A 1-year Trial to Inform About Long-term Exposure to Eptinezumab in Participants With Chronic Cluster Headache (cCH)

> **NCT05064397** · PHASE3 · COMPLETED · sponsor: **H. Lundbeck A/S** · enrollment: 131 (actual)

## Conditions studied

- Chronic Cluster Headache

## Interventions

- **DRUG:** Eptinezumab

## Key facts

- **NCT ID:** NCT05064397
- **Lead sponsor:** H. Lundbeck A/S
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-09-17
- **Primary completion:** 2023-06-29
- **Final completion:** 2023-06-29
- **Target enrollment:** 131 (ACTUAL)
- **Last updated:** 2024-08-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05064397

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05064397, "A 1-year Trial to Inform About Long-term Exposure to Eptinezumab in Participants With Chronic Cluster Headache (cCH)". Retrieved via AI Analytics 2026-05-30 from https://api.ai-analytics.org/clinical/NCT05064397. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*